This document is an excerpt from the EUR-Lex website
Document 62015CA0282
Case C-282/15: Judgment of the Court (Fourth Chamber) of 19 January 2017 (request for a preliminary ruling from the Verwaltungsgericht Braunschweig — Germany) — Queisser Pharma GmbH & Co. KG v Bundesrepublik Deutschland (Reference for a preliminary ruling — Free movement of goods — Articles 34 to 36 TFEU — Purely domestic situation — Food safety — Regulation (EC) No 178/2002 — Article 6 — Principle of risk analysis — Article 7 — Precautionary principle — Regulation (EC) No 1925/2006 — Member State legislation prohibiting the manufacture and sale of food supplements containing amino acids — Situation in which a temporary derogation to that prohibition is at the discretion of the national authority)
Case C-282/15: Judgment of the Court (Fourth Chamber) of 19 January 2017 (request for a preliminary ruling from the Verwaltungsgericht Braunschweig — Germany) — Queisser Pharma GmbH & Co. KG v Bundesrepublik Deutschland (Reference for a preliminary ruling — Free movement of goods — Articles 34 to 36 TFEU — Purely domestic situation — Food safety — Regulation (EC) No 178/2002 — Article 6 — Principle of risk analysis — Article 7 — Precautionary principle — Regulation (EC) No 1925/2006 — Member State legislation prohibiting the manufacture and sale of food supplements containing amino acids — Situation in which a temporary derogation to that prohibition is at the discretion of the national authority)
Case C-282/15: Judgment of the Court (Fourth Chamber) of 19 January 2017 (request for a preliminary ruling from the Verwaltungsgericht Braunschweig — Germany) — Queisser Pharma GmbH & Co. KG v Bundesrepublik Deutschland (Reference for a preliminary ruling — Free movement of goods — Articles 34 to 36 TFEU — Purely domestic situation — Food safety — Regulation (EC) No 178/2002 — Article 6 — Principle of risk analysis — Article 7 — Precautionary principle — Regulation (EC) No 1925/2006 — Member State legislation prohibiting the manufacture and sale of food supplements containing amino acids — Situation in which a temporary derogation to that prohibition is at the discretion of the national authority)
OJ C 70, 6.3.2017, p. 3–3
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 19/01/2017
- Date lodged:
- 11/06/2015
- Author:
- Court of Justice
- Form:
- Judicial information
- Authentic language:
- German
- Type of procedure:
- Reference for a preliminary ruling
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62015CJ0282
- Instruments cited in case law:
- Link
|
6.3.2017 |
EN |
Official Journal of the European Union |
C 70/3 |
Judgment of the Court (Fourth Chamber) of 19 January 2017 (request for a preliminary ruling from the Verwaltungsgericht Braunschweig — Germany) — Queisser Pharma GmbH & Co. KG v Bundesrepublik Deutschland
(Case C-282/15) (1)
((Reference for a preliminary ruling - Free movement of goods - Articles 34 to 36 TFEU - Purely domestic situation - Food safety - Regulation (EC) No 178/2002 - Article 6 - Principle of risk analysis - Article 7 - Precautionary principle - Regulation (EC) No 1925/2006 - Member State legislation prohibiting the manufacture and sale of food supplements containing amino acids - Situation in which a temporary derogation to that prohibition is at the discretion of the national authority))
(2017/C 070/03)
Language of the case: German
Referring court
Verwaltungsgericht Braunschweig
Parties to the main proceedings
Applicant: Queisser Pharma GmbH & Co. KG
Defendant: Bundesrepublik Deutschland
Operative part of the judgment
Articles 6 and 7 of Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety must be interpreted as precluding national legislation, such as that at issue in the main proceedings, which prohibits the manufacture, processing or marketing of any food supplement containing amino acids, unless a derogation has been issued by a national authority with discretion in that respect, where that legislation is based on a risk analysis which concerns only certain amino acids, which it is for the referring court to verify. In any event, those articles must be interpreted as precluding such national legislation, where that legislation lays down that the derogations to the prohibition covered by it may only be granted for a specific period even in cases where the safety of a substance is established.
